<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38690892</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.</ArticleTitle><Pagination><StartPage>354</StartPage><EndPage>363</EndPage><MedlinePgn>354-363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae159</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death through 28 days by 58%, of emergency department visits/hospitalizations/death through 14 days by 42%, and of long COVID through 10 months by 42%.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">COVID-OUT was a 2 &#xd7; 3 randomized, placebo-controlled, double-blind trial that assessed metformin, fluvoxamine, and ivermectin; 999 participants self-collected anterior nasal swabs on day 1 (n = 945), day 5 (n = 871), and day 10 (n = 775). Viral load was quantified using reverse-transcription quantitative polymerase chain reaction.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (-0.56 log10 copies/mL; 95% confidence interval [CI], -1.05 to -.06; P = .027). Those who received metformin were less likely to have a detectable viral load than placebo at day 5 or day 10 (odds ratio [OR], 0.72; 95% CI, .55 to .94). Viral rebound, defined as a higher viral load at day 10 than day 5, was less frequent with metformin (3.28%) than placebo (5.95%; OR, 0.68; 95% CI, .36 to 1.29). The metformin effect was consistent across subgroups and increased over time. Neither ivermectin nor fluvoxamine showed effect over placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this randomized, placebo-controlled trial of outpatient treatment of SARS-CoV-2, metformin significantly reduced SARS-CoV-2 viral load, which may explain the clinical benefits in this trial. Metformin is pleiotropic with other actions that are relevant to COVID-19 pathophysiology.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND">NCT04510194.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn T</ForeName><Initials>CT</Initials><Identifier Source="ORCID">0000-0001-5858-2080</Identifier><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckman</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Tanvi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karger</LastName><ForeName>Amy B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odde</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tignanelli</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Darrell M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Ray H B</ForeName><Initials>RHB</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Genomics Center, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebovitz</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicklas</LastName><ForeName>Jacinda M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Colorado, School of Medicine, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UnitedHealth Group, Optum Labs, Minnetonka, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puskarich</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belani</LastName><ForeName>Hrishikesh K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Olive View-University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Lianne K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klatt</LastName><ForeName>Nichole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blake</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Via</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Aubrey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Barkha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenno</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avula</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Neha V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Spencer M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fricton</LastName><ForeName>Regina D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Gwendolyn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>General Internal Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pullen</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherwood</LastName><ForeName>Nancy E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huling</LastName><ForeName>Jared D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-OUT Study Team
</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04510194</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK124654-01-A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2HL156812</GrantID><Agency>National Heart, Lung, and Blood Institute of the NIH</Agency><Country/></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Institute for Engineering in Medicine</Agency><Country/></Grant><Grant><Agency>Minnesota's Rainwater Foundation Grant</Agency><Country/></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Fast Grants</Agency><Country/></Grant><Grant><GrantID>K23 HL133604</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Olive View-</Agency><Country/></Grant><Grant><Agency>Edenbridge Pharmacy</Agency><Country/></Grant><Grant><Agency>Education and Research Institute</Agency><Country/></Grant><Grant><GrantID>OT2 HL156812</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-017069</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK124654</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002492</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA254849</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2HL161847</GrantID><Agency>NIH RECOVER</Agency><Country/></Grant><Grant><Agency>National Cancer Institute of the NIH</Agency><Country/></Grant><Grant><Agency>Subaward of the University</Agency><Country/></Grant><Grant><Agency>Rainwater Charitable Foundation</Agency><Country/></Grant><Grant><GrantID>T32HL129956</GrantID><Agency>National Heart, Lung, and Blood Institute of the NIH</Agency><Country/></Grant><Grant><Agency>Leidos Biomedical</Agency><Country/></Grant><Grant><Agency>Apotex Pharmacy</Agency><Country/></Grant><Grant><GrantID>00086722</GrantID><Agency>Minnesota Partnership for Biotechnology and Medical Genomics</Agency><Country/></Grant><Grant><GrantID>KL2TR002492</GrantID><Agency>UnitedHealth Group Foundation</Agency><Country/></Grant><Grant><Agency>Parsemus Foundation</Agency><Country/></Grant><Grant><GrantID>R21 LM012744</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA210190</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Infect Dis. 2024 Aug 16;79(2):292-294. doi: 10.1093/cid/ciae154</RefSource><PMID Version="1">38690870</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="N">Fluvoxamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">mTOR</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">outpatient COVID-19 treatment</Keyword><Keyword MajorTopicYN="N">viral load</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. J. B. B. reports contracted fees and travel support for contracted activities for consulting work paid to the University of North Carolina by Novo Nordisk; grant support by NIH, PCORI, Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; personal compensation for consultation from Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Mellitus Health, Metsera, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, and Vertex.; personal compensation for expert testimony from Medtronic MiniMed; participation on advisory boards for Altimmune, AstraZeneca, and Insulet; a leadership role for the Association of Clinical and Translational Science; and stock/options in Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. M. A. P. receives consulting fees from Opticyte and Cytovale. A. B. K. has served as an external consultant for Roche Diagnostics; received speaker honoraria from Siemens Healthcare Diagnostics, the American Kidney Fund, the National Kidney Foundation, the American Society of Nephrology, and Yale University Department of Laboratory Medicine; research support unrelated to this work from Siemens Healthcare Diagnostics, Kyowa Kirin Pharmaceutical Development, the Juvenile Diabetes Research Foundation, and the NIH; support for travel from College of American Pathologists Point-Of-Care Testing Committee; participation on an advisory board for the Minnesota Newborn Screening Advisory Committee; grants from NIH and JDRF for multiple unrelated clinical research projects and Kyowa Kirin Pharmaceutical Development and Siemens Healthcare Diagnostics for unrelated clinical research studies; and leadership roles for the American Board of Clinical Chemistry, Association for Diagnostics and Laboratory Medicine (ADLM) Evidence-Based Laboratory Medicine Subcommittee, and ADLM Academy Test Utilization Committee. M. R. R. reports consulting fees from 20/20 Gene Systems for coronavirus disease 2019 testing. D. B. R. reports grants from the NIH NCATS ACTIV-6 Steering Committee Chair. K. C. reports stock or stock options for United Health Group. C. T. B. reports consulting fees from NCATS/DCRI and the ACTIV-6 Executive Committee and support for travel from Academic Medical Education. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blake</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atwater</LastName><ForeName>Riannon C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avula</LastName><ForeName>Nandini</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckman</LastName><ForeName>Kenny B</ForeName><Initials>KB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belani</LastName><ForeName>Hrishikesh K</ForeName><Initials>HK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn T</ForeName><Initials>CT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brea</LastName><ForeName>Jannis</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Broedlow</LastName><ForeName>Courtney A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campora</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Challa</LastName><ForeName>Anup</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charles</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christensen</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connelly</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Datta</LastName><ForeName>Srijani</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deng</LastName><ForeName>Nikita</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunn</LastName><ForeName>Alex T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erickson</LastName><ForeName>Spencer M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairbairn</LastName><ForeName>Faith M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenno</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fraser</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fricton</LastName><ForeName>Regina D</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Gwen</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagen</LastName><ForeName>Aubrey A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendrickson</LastName><ForeName>Audrey F</ForeName><Initials>AF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huling</LastName><ForeName>Jared D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingraham</LastName><ForeName>Nicholas E</ForeName><Initials>NE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeng</LastName><ForeName>Arthur C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Darrell M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karger</LastName><ForeName>Amy B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klatt</LastName><ForeName>Nichole R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuehl</LastName><ForeName>Erik A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaBar</LastName><ForeName>Derek D</ForeName><Initials>DD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liebovitz</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindberg</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luke</LastName><ForeName>Darlette G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Machicado</LastName><ForeName>Rosario</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohamud</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ngonyama</LastName><ForeName>Rumbidzai</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicklas</LastName><ForeName>Jacinda M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odde</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parrens</LastName><ForeName>Elliott</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parra</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Barkha</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proper</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pullen</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puskarich</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Via</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>Neha V</ForeName><Initials>NV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>Naveen</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rypka</LastName><ForeName>Katelyn J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saveraid</LastName><ForeName>Hanna G</ForeName><Initials>HG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seloadji</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shahriar</LastName><ForeName>Arman</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherwood</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siegart</LastName><ForeName>Jamie L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siegel</LastName><ForeName>Lianne K</ForeName><Initials>LK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simmons</LastName><ForeName>Lucas</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinelli</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>Palak</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stauffer</LastName><ForeName>Maxwell T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tignanelli</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tople</LastName><ForeName>Tannon L</ForeName><Initials>TL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tordsen</LastName><ForeName>Walker J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>Ray H B</ForeName><Initials>RHB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Beiqing</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaman</LastName><ForeName>Adnin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zolik</LastName><ForeName>Madeline R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zinkl</LastName><ForeName>Lena</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>16</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>1</Day><Hour>13</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>1</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38690892</ArticleId><ArticleId IdType="pmc">PMC11327787</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae159</ArticleId><ArticleId IdType="pii">7660393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. . Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. New Engl J Med 2022; 387:599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle BT, Dock C, Hemmat M, et al. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv 111237 [Preprint]. June 16, 2020. Available from: 10.1101/2020.05.22.111237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.22.111237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, et al. . A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020; 583:459&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller MA, Sharma Y, Dupee Z, et al. . Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses. JCI Insight 2021; 6:e148003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492301</ArticleId><ArticleId IdType="pubmed">34357881</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JJ, Hellberg K, Turner M, et al. . Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab 2017; 25:463&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299044</ArticleId><ArticleId IdType="pubmed">28089566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CJ. Metformin: historical overview. Diabetologia 2017; 60:1566&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">28776081</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia EY. Flumamine, a new synthetic analgesic and antiflu drug. Philippine Med Assoc 1950; 26:287&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">14779282</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Singh PK, Suhail H, et al. . AMP-activated protein kinase restricts Zika virus replication in endothelial cells by potentiating innate antiviral responses and inhibiting glycolysis. J Immunol 2020; 204:1810&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7310572</ArticleId><ArticleId IdType="pubmed">32086387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Ramos da Silva S, Huang IC, Jung JU, Gao SJ. Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22. J Virol 2018; 92:e02019&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790943</ArticleId><ArticleId IdType="pubmed">29212931</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo JA, Garc&#xed;a-Valdecasas M, Gil-G&#xf3;mez A, et al. . Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS One 2018; 13:e0191805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5791999</ArticleId><ArticleId IdType="pubmed">29385181</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese K. The mechanistic target of rapamycin (mTOR): novel considerations as an antiviral treatment. Curr Neurovasc Res 2020; 17:332&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541431</ArticleId><ArticleId IdType="pubmed">32334502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, et al. . Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis 2023; 23:1119&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannan N, Raihan R, Parvin US, et al. . Detection of SARS-CoV-2 RNA by reverse transcription-polymerase chain reaction (RT-PCR) on self-collected nasal swab compared with professionally collected nasopharyngeal swab. Cureus 2022; 14:e25618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9249011</ArticleId><ArticleId IdType="pubmed">35784954</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil Mart&#xed;nez V, Avedillo Salas A, Santander Ballest&#xed;n S. Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review. Pharmaceuticals (Basel) 2021; 14:736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8398077</ArticleId><ArticleId IdType="pubmed">34451833</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Rossello X, Owen R, Collier TJ, Stone GW, Rockhold FW. Primary and secondary outcome reporting in randomized trials: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78:827&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">34412817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Stone GW. The primary outcome fails&#x2014;what next? New Engl J Med 2016; 375:861&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27579636</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl&#xf6;f B, Devereux RB, Kjeldsen SE, et al. . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">11937178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-Lopez C, Cervantes-Luevano K, Aguirre-Sanchez JS, et al. . Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in vitro model and randomized, double-blind, phase IIb clinical trial. Biomed Pharmacother 2022; 152:113223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res 2022; 323:199010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. . Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized platform clinical trial. Lancet Reg Health Am 2022; 6:100142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8668402</ArticleId><ArticleId IdType="pubmed">34927127</ArticleId></ArticleIdList></Reference><Reference><Citation>Expression of concern &#x2013; Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized platform clinical trial. Lancet Reg health Am 2024; 31:100703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8668402</ArticleId><ArticleId IdType="pubmed">34927127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills EJ. Email communications to D. Boulware and C. Bramante on 1/5/24, 1/12/24.</Citation></Reference><Reference><Citation>Henry RR, Frias JP, Walsh B, et al. . Improved glycemic control with minimal systemic metformin exposure: effects of metformin delayed-release (metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One 2018; 13:e0203946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155522</ArticleId><ArticleId IdType="pubmed">30252913</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA, Buse JB, Kim T, et al. . Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 2016; 59:1645&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930485</ArticleId><ArticleId IdType="pubmed">27216492</ArticleId></ArticleIdList></Reference><Reference><Citation>Buse JB, DeFronzo RA, Rosenstock J, et al. . The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 2016; 39:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">26285584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. . Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. New Engl J Med 2022; 386:1397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. . Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. New Engl J Med 2022; 386:509&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ 2016; 352:i1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">27121591</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-P&#xe9;rez M-J, Saiz J-C, Priego E-M, Mart&#xed;n-Acebes MA. Antivirals against (re)emerging flaviviruses: should we target the virus or the host? ACS Med Chem Lett 2022; 13:5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8762743</ArticleId><ArticleId IdType="pubmed">35059112</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues TS, de Sa KSG, Ishimoto AY, et al. . Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med 2021; 218:e20201707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun B, Shin S, Lee A, et al. . Metformin down-regulates TNF-&#x3b1; secretion via suppression of scavenger receptors in macrophages. Immune Netw 2013; 13:123&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759709</ArticleId><ArticleId IdType="pubmed">24009539</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian H, Liu Y, Rundberg Nilsson A, et al. . Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity 2021; 54:1463&#x2013;77.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189765</ArticleId><ArticleId IdType="pubmed">34115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnette KG, Gordon Michael S, Rodriguez D, et al. . Oral sabizabulin for high-risk, hospitalized adults with Covid-19: interim analysis. NEJM Evidence 2022; 1:EVIDoa2200145.</Citation><ArticleIdList><ArticleId IdType="pubmed">38319812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Proper JL, Boulware DR, et al. . Vaccination against SARS-CoV-2 is associated with a lower viral load and likelihood of systemic symptoms. Open Forum Infect Dis 2022; 9:ofac066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982774</ArticleId><ArticleId IdType="pubmed">35392460</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto M, Perencevich EN. Metformin and infections: what is the next step in this decades-long story? Clin Infect Dis 2023; 76:1245&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">36560871</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed T, Bowe M, Plant A, Perez M, Alvarez CA, Mortensen EM. Metformin use is associated with lower mortality in veterans with diabetes hospitalized with pneumonia. Clin Infect Dis 2023; 76:1237&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10319762</ArticleId><ArticleId IdType="pubmed">36575139</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J-W, Sun L-J, Zhao Y-H, Kang P, Yan B-Z. The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. Int J Infect Dis 2012; 16:e436&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22486858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wabitsch S, McCallen JD, Kamenyeva O, et al. . Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol 2022; 77:748&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9391315</ArticleId><ArticleId IdType="pubmed">35378172</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Wang X, Chen Y, et al. . Metformin modulates T cell function and alleviates liver injury through bioenergetic regulation in viral hepatitis. Front Immunol 2021; 12:638575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8097169</ArticleId><ArticleId IdType="pubmed">33968030</ArticleId></ArticleIdList></Reference><Reference><Citation>Boggess KA, Valint A, Refuerzo JS, et al. . Metformin plus insulin for preexisting diabetes or gestational diabetes in early pregnancy: the MOMPOD randomized clinical trial. JAMA 2023; 330:2182&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10716718</ArticleId><ArticleId IdType="pubmed">38085312</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne F, Newman C, Alvarez-Iglesias A, et al. . Early metformin in gestational diabetes: a randomized clinical trial. JAMA 2023; 330:1547&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10548359</ArticleId><ArticleId IdType="pubmed">37786390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauras N, DelGiorno C, Hossain J, et al. . Metformin use in children with obesity and normal glucose tolerance&#x2014;effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab 2012; 25:33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005723</ArticleId><ArticleId IdType="pubmed">22570948</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith FC, Stocker SL, Danta M, et al. . The safety and pharmacokinetics of metformin in patients with chronic liver disease. Aliment Pharmacol Ther 2020; 51:565&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">31960986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Harmsen WS, Mettler TA, et al. . Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60:2008&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4218882</ArticleId><ArticleId IdType="pubmed">24798175</ArticleId></ArticleIdList></Reference><Reference><Citation>Eurich DT, Weir DL, Majumdar SR, et al. . Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6:395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">23508758</ArticleId></ArticleIdList></Reference><Reference><Citation>Clegg LE, Jing Y, Penland RC, et al. . Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. Diabetes Obes Metab 2021; 23:1101&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">33394543</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LL, Umpierrez GE, Inzucchi SE. Management of hyperglycemia in hospitalized, non-critically ill adults. New Engl J Med 2022; 387:1040&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">36103419</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz KM, Marroquin OC, Zenati MS, et al. . Association between preoperative metformin exposure and postoperative outcomes in adults with type 2 diabetes. JAMA Surgery 2020; 155:e200416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142798</ArticleId><ArticleId IdType="pubmed">32267474</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanasamy S, Curtis LH, Hernandez AF, et al. . Lessons from COVID-19 for pandemic preparedness: proceedings from a multistakeholder think tank. Clin Infect Dis 2023; 77:1635&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10724451</ArticleId><ArticleId IdType="pubmed">37435958</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>